"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone ...

CREST: Significant EFS boost seen with sasanlimab plus BCG in NMIBC ...

ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...

Clinical benefit rate was observed 5 (27%) patients in cohort 1, 7 (27%) patients in cohort 2, and 2 (11%) patients in cohort 3.

Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important ...

Testosterone replacement therapy may not increase prostate cancer recurrence risk, but evidence remains inconclusive, necessitating individualized treatment plans. Bipolar androgen therapy (BAT) ...

Dr. Shawn Zimberg and Dr. Dean Laganosky discuss the BioProtect Balloon Transplant System, a rectal spacer for use in prostate cancer radiation. Laganosky: The BioProtect rectal spacing device is a ...

The decline in total testosterone was observed even among men with normal body mass index. From 1999 to 2016, testosterone levels have declined in adolescent and young adult men (AYA), according to ...

Another year of above-average inflation led the Internal Revenue Service to issue meaningful cost-of-living adjustments to Social Security benefits, retirement plan contribution limits, and other ...

“This was a positive study, resulting in a statistically significant improvement in the primary end point of rPFS in the intent-to-treat population," said Rana R. McKay, MD, FASCO.